PepGen ends Duchenne drug program after weak Phase 2 results, pivots to DM1 treatment showing early signs of splicing ...

Boston-based biotech PepGen Inc. (NASDAQ:PEPG) announced today it will discontinue all Duchenne muscular dystrophy (DMD) ...

PepGen Inc. (NASDAQ:PEPG) will now focus on its promising myotonic dystrophy type 1 (DM1) program, PGN-EDODM1 ... lies in the belief that some AI stocks hold greater promise for delivering ...

Dynavax Technologies Corporation , a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at William Blair's ...

NanoVibronix, Inc. (the "Company") confirmed that a series of posts made earlier today with respect to a $26 million registered direct offering of common stock of the Company priced at $0.45 under ...

BOSTON - PepGen Inc. (NASDAQ:PEPG), a biotech firm focusing on oligonucleotide therapies for neuromuscular and neurological diseases, today announced ... While the stock has faced significant ...

PepGen (PEPG) announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy patients ...

today announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) patients ...

PGN’s customer base continues to expand, now serving 823,298 customers across Indonesia, including 3,291 industrial and commercial customers, 2,587 small businesses, and 817,420 households. The ...

U.S. equities gave up morning gains and were mixed at midday following a federal trade court ruling blocking some of ...